Остеопороз в практике пульмонолога


И.А. Баранова

Кафедра госпитальной терапии педиатрического факультета РНИМУ им. Н.И. Пирогова Минздрава России, Москва
Обзор посвящен проблеме вторичного остеопороза (ОП) в практике врача-пульмонолога. Это заболевание может быть обусловлено приемом глюкокортикостероидов, прежде всего пероральных, а также развиваться вне зависимости от проводимой терапии как осложнение тяжелого течения заболевания. ОП как коморбидное заболевание рассматривается при хронической обструктивной болезни легких, бронхиальной астме, муковисцидозе, саркоидозе, интерстициальных легочных заболеваниях, у больных, нуждающихся в трансплантации легких. Представлены рекомендации по диагностике ОП, профилактике и лечению его глюкокортикоидной формы.

Литература



  1. Kanis JA. Smoking and fracture risk: a meta-analysis Osteoporos Int 2005;16(2):155–62.

  2. Barnes PJ, Celli BR. Systemic manifestation and comorbidities of COPD. Eur Respir J 2009;33:1165–85.

  3. Kong YY. Molecular control of bone remodeling and osteoporosis. Exp Gerontol 2000;35(8):947–56.

  4. Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:1259–65.

  5. Bolton CE, Ionescu AA, Shiels KM, et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:1286–93.

  6. Graat-Verboom EFM, Wouters FWJM, Smeenk, et al. Current status of research on osteoporosis in COPD: a systematic review. J Respir J 2009;34:209–18.

  7. Nuti R. Vertebral fractures in patients with chronic obstructive pulmonary disease: the EOLO Study. Osteoporos Int 2009;20(6):989–98.

  8. Kjensli A, Falch JA, Ryg M, et al. High prevalence of vertebral deformities in COPD patients: relationship to disease severity. Eur Respir J 2009;33:1018–24.

  9. Dam TT. Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma. Osteoporos Int 2010;21(8):1341–49.

  10. Cystic Fibrosis Foundation, Patient Registry 2010.

  11. Annual Report, Cystic Fibrosis Foundation, Bethesda, Md, USA, 2012.

  12. Shead EF, Haworth CS, Gunn E, et al. Osteoclastogenesis during infective exacerbations in patients with cystic fibrosis. Am J Respir Crit Care Med 2006;174:306–11.

  13. Shead EF, Haworth CS, Barker H, et al. Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis. J Cyst Fibros 2010;9:93–8.

  14. King SL, Topliss DJ, Kotsimbos T, et al. Reduced bone density in cystic fibrosis: ∆F508 mutation is an independent risk factor. Eur Respir J 2005;25:54–61.

  15. Aris RM, Guise TA. Cystic fibrosis and bone disease: are we missing a genetic link? Eur Respir J 2005;25(1):9–11.

  16. Shead EF, Haworth CS, Condliffe AM, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone. Thorax 2007;62:650–51.

  17. Le Heron L, Guillaume C, Velard F, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) regulates the production of osteoprotegerin (OPG) and prostaglandin (PG) E2 in human bone. J Cyst Fibros 2010;9:69–72.

  18. Aris RM, Renner JB, Winders AD, et al. Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis. Ann Int Med 1998;128(3):186–93.

  19. Aringer M, Kiener HP, Koeller MD, et al. High turnover bone disease following lung transplantation. Bonе 1998;23(5):485–88.

  20. Buntain HM, Greer RM, Schluter PJ, et al. Bone mineral density in Australian children, adolescents and adults with cystic fibrosis: a controlled cross sectional study. Thorax 2004;59:149–55.

  21. Красовский С.А., Баранова И.А., Амелина Е.Л. и др. Минеральная плотность костной ткани, частота деформаций позвонков и периферических переломов у взрослых больных муковисцидозом // Пульмонология 2011. № 5. С. 71–8.

  22. Paccou J, Zeboulon N, Combescure C, et al. The prevalence of osteoporosis, osteopenia, and fractures: a systematic literature review with meta-analysis. Calcif Tissue Int 2010;86:1–7.

  23. Elkin SL, Fairney A, Burnett S, et al. Vertebral deformities and low bone mineral density in adults with cystic fibrosis: a cross-sectional study. Osteoporos Int 2001;12:366–72.

  24. Stephenson A, Jamal S, Dowdell T, et al. Prevalence of vertebral fractures in adults with cystic fibrosis and their relationship to bone mineral density. Chest 2006;130:539–44.

  25. Aris RM, Merkel PA, Bachrach LK, et al. Consensus statement: Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab 2005;90(3):1888–96.

  26. Report of the UK Cystic Fibrosis Trust Bone Mineralisation Working Group. Bone mineralisation in cystic fibrosis. Cystic Fibrosis Trust. 2007.

  27. Саркоидоз / Под ред. А.А.Визеля. Серия монографий Российского респираторного общества. Гл. ред. серии А.Г. Чучалин М., 2010. 416 с.

  28. Burke RR, Rybicki BA, Rao DS. Calcium and vitamin D in sarcoidosis: how to assess and manage. Semin Respir Crit Care Med 2010;31:474–84.

  29. Conron M. Calcium metabolism in sarcoidosis and its clinical implications. Rheumatology (Oxford) 2000;39(7):707–13.

  30. Sweiss NJ, Lower EE, Korsten P, et al. Bone health issues in sarcoidosis. Curr Rheumatol Rep 2011;13:265–72.

  31. Pauwels RA, Lofdahl C-G, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999;340(25):1948–53.

  32. Ferguson GT, Calverley PMA, Anderson JA, et al Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest 2009;136(6):1456–65.

  33. Jones A, Fay JK, Burr M, et al. Inhaled corticosteroid effects on bone metabolism in asthma and mild obstructive pulmonary disease. Cochrane Library 2002;3:CD003537.

  34. Weatherall M. Dose-response relationship for risk of non-vertebral fracture with inhaled corticosteroids. Clin Exp Allergy 2008;38(9): 1451–58.

  35. Остеопороз / Под ред. О.М. Лесняк, Л.И. Беневоленской. 2-е изд. М., 2009. 272 с

  36. http://www.ginasthma.org/uploads/users/files/GINA_Russian_2011.pdf

  37. van Staa TP, Leufkens HG, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000;39:1383–89.

  38. Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000,15: 933–1000.

  39. Лесняк О.М., Баранова И.А., Торопцова Н.В. Клинические рекомендации «Диагностика, профилактика и лечение глюкокортикоидного остеопороза у мужчин и женщин 18 лет и старше». Ярославль, 2013.

  40. International Guidelines for the selection of lung transplant candidates. 1998.

  41. International Guidelines for the Selection of Lung Transplant Candidates: 2006 Update – A Consensus Report From the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. 2006.

  42. Ebeling PR. Approach to the patient with transplantation-related bone loss J Clin Endocrinol Metab 2009;94:1483–90.

  43. Ebeling PR. Transplantation osteoporosis In: Rosen CJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 7th ed. Chap. 61. Washington, DC: American Society for Bone Mineral Research; 2008:279–85.

  44. Shane E, Papadopoulos A, Staron RB et al. Bone loss and fracture after lung transplantation 1999;68:220–27.

  45. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004;19:893–99.

  46. Kanis JA, Johansson H, Oden A, et al. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 2011;22:809–16.

  47. Клинические рекомендации по профилактике и ведению больных с остеопорозом / Под ред О.М. Лесняк. Ярославль, 2012. 24 с.


Об авторах / Для корреспонденции


Автор для связи: И.А. Баранова – д.м.н., проф. кафедры; e-mail: baranova@ro.ru


Похожие статьи


Бионика Медиа